nisotirostide (LY3457263) / Eli Lilly - LARVOL DELTA

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide (clinicaltrials.gov) - P2 | N=240 | Active, not recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 Compared with Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1 | N=94 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 in Obese Participants (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of LY3457263 in Obese Participants (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Genetic Disorders • Obesity

A Study of LY3457263 in Obese Participants (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Genetic Disorders • Obesity

A Study of LY3457263 in Obese Participants (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Eli Lilly and Company

Combination therapy • New P1 trial • Genetic Disorders • Obesity

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1 | N=86 | Not yet recruiting | Sponsor: Eli Lilly and Company

Combination therapy • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=67; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=90; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus